
Fanny Collaud

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3784953/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vector. Molecular Therapy - Methods and Clinical Development, 2021, 20, 169-180.	4.1	12
2	Efficacy of AAV8-hUGT1A1Âwith Rapamycin in neonatal, suckling, and juvenile rats to model treatment in pediatric CNs patients. Molecular Therapy - Methods and Clinical Development, 2021, 20, 287-297.	4.1	9
3	Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates. Nature Communications, 2021, 12, 6393.	12.8	14
4	Gene therapy with secreted acid alpha-glucosidase rescues Pompe disease in a novel mouse model with early-onset spinal cord and respiratory defects. EBioMedicine, 2020, 61, 103052.	6.1	14
5	Singleâ€domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors. EMBO Molecular Medicine, 2020, 12, e11298.	6.9	20
6	lgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nature Medicine, 2020, 26, 1096-1101.	30.7	193
7	Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-Glucosidase. Molecular Therapy, 2020, 28, 2056-2072.	8.2	16
8	Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler–Najjar Syndrome. Human Gene Therapy, 2019, 30, 1297-1305.	2.7	39
9	Role of Regulatory T Cell and Effector T Cell Exhaustion in Liver-Mediated Transgene Tolerance in Muscle. Molecular Therapy - Methods and Clinical Development, 2019, 15, 83-100.	4.1	16
10	AAV Gene Transfer with Tandem Promoter Design Prevents Anti-transgene Immunity and Provides Persistent Efficacy in Neonate Pompe Mice. Molecular Therapy - Methods and Clinical Development, 2019, 12, 85-101.	4.1	52
11	Dual muscle-liver transduction imposes immune tolerance for muscle transgene engraftment despite preexisting immunity. JCI Insight, 2019, 4, .	5.0	17
12	Progress and challenges of gene therapy for Pompe disease. Annals of Translational Medicine, 2019, 7, 287-287.	1.7	35
13	Rescue of GSDIII Phenotype with Gene Transfer Requires Liver- and Muscle-Targeted GDE Expression. Molecular Therapy, 2018, 26, 890-901.	8.2	24
14	Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nature Communications, 2018, 9, 4098.	12.8	184
15	Exposure to wild-type AAV drives distinct capsid immunity profiles in humans. Journal of Clinical Investigation, 2018, 128, 5267-5279.	8.2	76
16	Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase. Science Translational Medicine, 2017, 9, .	12.4	103
17	Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors. Blood Advances, 2017, 1, 2019-2031.	5.2	90
18	77. Antigen-Specific Modulation of Capsid Immunogenicity with Tolerogenic Nanoparticles Results in Successful AAV Vector Readministration. Molecular Therapy, 2016, 24, S34.	8.2	8

#	Article	IF	CITATIONS
19	A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16049.	4.1	50